Kranias Chairs NIH Study Section

Litsa Kranias, PhD, Hanna Professor, Distinguished University Research Professor in the Department of Pharmacology and Cell Biophysics and Co-Director of the Cardiovascular Center of Excellence, has been appointed Chair of the Cardiac Contractility, Hypertrophy and Heart Failure (CCHF) study section of the National Institutes of Health. The appointment is until July 2017. Section chairs are chosen on the basis of their demonstrated leadership in the field, strong record of NIH funding and scholarly publications, broad scientific perspective, reputation for integrity and fairness, respect by the scientific review officers panel, willingness to support NIH review policies, and the ability to appropriately manage meetings, review presentations and summarize discussion. The CCHF Study Section reviews applications to the NIH that involve basic, applied and translational aspects of heart function, homeostasis and disease. Applications focus on contractile function and dysfunction, including studies of hereditary and acquired cardiac hypertrophy and failure, at levels ranging from molecular assemblies to the intact organ to translation of novel therapies to human. 

Litsa Kranias, PhD, has been named a 2009 American Heart Association Distinguished Scientist.

Litsa Kranias, PhD, has been named a 2009 American Heart Association Distinguished Scientist.

Litsa Kranias, PhD, says performing genetic  surgery  on part of a molecule that inhibits a certain protein s function could lead to a new treatment for heart failure.

Litsa Kranias, PhD, says performing genetic  surgery on part of a molecule that inhibits a certain protein s function could lead to a new treatment for heart failure.

Tags

Related Stories

1

Study: Additional radiation for liver cancer does not increase toxicity

March 10, 2026

New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.

2

Is uACR the key to cardiovascular and kidney disease prevention?

March 8, 2026

As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.

3

Driven by her own pain

March 8, 2026

Endometriosis is a painful and often debilitating disease that affects an estimated 6.5 million women in the U.S. It occurs when tissue similar to the lining of the uterus grows outside of it, causing pain, inflammation and sometimes infertility. Now a University of Cincinnati College of Medicine researcher is developing what is believed to be the first at-home diagnostic test.